Dublin, Ireland

Time filter

Source Type

Trino Therapeutics | Entity website

May 28, 2013 by admin in News TRINO THERAPEUTICS secures Series A investment of over9M ($12M) for a novel oral drug therapy for mild to moderate ulcerative colitis Irelands Trino Therapeutics secures major additional investment from new investors Fountain Healthcare Partners and founding investor the Wellcome Trust; Wellcome Trust will invest through the prestigious internationally competitive Strategic Read More


Trino Therapeutics | Entity website

Trino Therapeutics is a spin-off company from the School of Pharmacy and Pharmaceutical Sciences, Trinity College Dublin(TCD). Launched in September 2011, itis supported by a syndicate of Venture Capital investors and local State Support thatincludes Fountain Healthcare Partners, The Wellcome Trust, Growcorp and Enterprise Ireland


PubMed | Trino Therapeutics, Trinity College Dublin and University of Bradford
Type: | Journal: Journal of molecular structure | Year: 2015

The single enantiomer (1


Trino Therapeutics | Entity website

Contact Details Richard Davis, Chief Executive Officer Address The Tower, Trinity Technology and Enterprise Campus, Pearse Street, Dublin 2 Tel +353 1 6709865 Email rdavis@trinotherapeutics.com View Trino Therapeutics in a larger map


Trino Therapeutics | Entity website

Welcome to Trino Therapeutics Irelands Trino Therapeutics is a privately held biotech company focused on developing oral small molecules for the treatment and unmet management of inflammatory bowel disease (IBD) and other inflammatory indications. Trino was initially spun out of Trinity College Dublin with seed investment,support from Enterprise Ireland and translational funding from Wellcome Trust Innovations ...


November 03, 2014 by admin in News Dr Richard Davis appointed in the newly created role of Chief Executive Officer Industry recognised clinical expert, Dr Marie Lindner appointed as a non-executive to the Board of Directors Trino Therapeutics lead candidate, PH46A, advances in an extended Phase I clinical trial DUBLIN, Ireland. 3rd November 2014 ...


Trino Therapeutics | Entity website

November 03, 2014 by admin in News Dr Richard Davis appointed in the newly created role of Chief Executive Officer Industry recognised clinical expert, Dr Marie Lindner appointed as a non-executive to the Board of Directors Trino Therapeutics lead candidate, PH46A, advances in an extended Phase I clinical trial DUBLIN, Ireland. 3rd November 2014 ...


Dr Richard Davis appointed in the newly created role of Chief Executive Officer Industry recognised clinical expert, Dr Marie Lindner appointed as a non-executive to the Board of Directors Trino Therapeutics lead candidate, PH46A, advances in an extended Phase I clinical trial DUBLIN, Ireland. 3rd November 2014 ...


Trino Therapeutics | Entity website

Piers Morgan, Trino Chairman Piers Morgan was appointed Chairman of Trino in February 2012. He is CEO of C4X Discovery Holdings plc, a drug discovery and development company and led its listing on AIM in October 2014 ...

Loading Trino Therapeutics collaborators
Loading Trino Therapeutics collaborators